gabapentin has been researched along with Cough in 31 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity." | 9.51 | The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial. ( Gao, R; Pu, J; Shi, C; Tang, J; Wang, S; Wang, X; Wen, S; Xu, X; Yu, L; Zhu, Y, 2022) |
| "The goal of this study was to evaluate the effectiveness of gabapentin (GBT) alone and in combination with montelukast (MTL) for improving cough." | 9.51 | The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19- related cough: A randomized, controlled clinical trial. ( Dolatshahi, K; Hakamifard, A; Khorvash, F; Nasirharandi, S; Nasirian, M; Soltani, R, 2022) |
| "To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough." | 9.30 | Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| " Both high and low doses of gabapentin administration could reduce cough hypersensitivity exposed to HCl perfusion, attenuate airway inflammatory damage, and inhibit neurogenic inflammation by reducing SP expression from the airway and vagal ganglia." | 8.31 | Gabapentin alleviated the cough hypersensitivity and neurogenic inflammation in a guinea pig model with repeated intra-esophageal acid perfusion. ( Chen, R; Chen, Z; Dong, J; Huang, J; Ji, X; Xu, Y; Yan, W; Zhan, C; Zheng, Z; Zhi, H; Zhong, M, 2023) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity." | 5.51 | The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial. ( Gao, R; Pu, J; Shi, C; Tang, J; Wang, S; Wang, X; Wen, S; Xu, X; Yu, L; Zhu, Y, 2022) |
| "The goal of this study was to evaluate the effectiveness of gabapentin (GBT) alone and in combination with montelukast (MTL) for improving cough." | 5.51 | The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19- related cough: A randomized, controlled clinical trial. ( Dolatshahi, K; Hakamifard, A; Khorvash, F; Nasirharandi, S; Nasirian, M; Soltani, R, 2022) |
| "To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough." | 5.30 | Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| ", opioids and gabapentin) are centrally-acting drugs primarily used for pain and neuropathic conditions; they were not designed for cough and have limitations with respect to efficacy and safety." | 5.05 | Pharmacotherapeutic Options for Chronic Refractory Cough. ( Chung, KF; Song, WJ, 2020) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| " Both high and low doses of gabapentin administration could reduce cough hypersensitivity exposed to HCl perfusion, attenuate airway inflammatory damage, and inhibit neurogenic inflammation by reducing SP expression from the airway and vagal ganglia." | 4.31 | Gabapentin alleviated the cough hypersensitivity and neurogenic inflammation in a guinea pig model with repeated intra-esophageal acid perfusion. ( Chen, R; Chen, Z; Dong, J; Huang, J; Ji, X; Xu, Y; Yan, W; Zhan, C; Zheng, Z; Zhi, H; Zhong, M, 2023) |
| "Objective To evaluate the short- and long-term effects of tricyclic antidepressants (TCAs) and gabapentin in the treatment of unexplained chronic cough (UCC)." | 3.88 | Short- and Long-term Effects of Neuromodulators for Unexplained Chronic Cough. ( Adessa, M; Benninger, MS; Bowen, AJ; Bryson, PC; Contrera, K; Kaltenbach, J; Milstein, CF; Nowacki, AS; Taliercio, R; Trask, D, 2018) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Cough is a common respiratory symptom that is considered to be chronic when it lasts more than eight weeks." | 2.66 | Management of chronic refractory cough in adults. ( Beghè, B; Fabbri, LM; Papi, A; Spanevello, A; Visca, D, 2020) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Chronic refractory cough has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition." | 2.52 | Management of chronic refractory cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is often attributed to reflux, postnasal drip, or asthma." | 1.33 | Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. ( Lee, B; Woo, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 10 (32.26) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, R | 1 |
| Xu, X | 3 |
| Wang, S | 1 |
| Pu, J | 1 |
| Shi, C | 2 |
| Wen, S | 1 |
| Zhu, Y | 1 |
| Tang, J | 1 |
| Wang, X | 1 |
| Yu, L | 3 |
| Soltani, R | 2 |
| Nasirharandi, S | 1 |
| Khorvash, F | 1 |
| Nasirian, M | 1 |
| Dolatshahi, K | 1 |
| Hakamifard, A | 2 |
| Ito, S | 3 |
| Shimamura, Y | 3 |
| Matsumoto, H | 3 |
| Guilleminault, L | 1 |
| Demoulin-Alexikova, S | 1 |
| de Gabory, L | 1 |
| Bruley des Varannes, S | 1 |
| Brouquières, D | 1 |
| Balaguer, M | 1 |
| Chapron, A | 1 |
| Grassin Delyle, S | 1 |
| Poussel, M | 1 |
| Guibert, N | 1 |
| Reychler, G | 1 |
| Trzepizur, W | 1 |
| Woisard, V | 1 |
| Crestani, S | 1 |
| Zhi, H | 1 |
| Zhong, M | 1 |
| Huang, J | 1 |
| Zheng, Z | 1 |
| Ji, X | 1 |
| Xu, Y | 1 |
| Dong, J | 1 |
| Yan, W | 1 |
| Chen, Z | 1 |
| Zhan, C | 1 |
| Chen, R | 1 |
| Lee, MY | 1 |
| Taliercio, RM | 1 |
| Adessa, M | 2 |
| Milstein, C | 1 |
| Bryson, PC | 2 |
| Song, WJ | 1 |
| Chung, KF | 2 |
| Zheng, C | 1 |
| Childers, J | 1 |
| Rabinovich, E | 1 |
| Nazareth-Pidgeon, K | 1 |
| Visca, D | 1 |
| Beghè, B | 1 |
| Fabbri, LM | 1 |
| Papi, A | 1 |
| Spanevello, A | 1 |
| Giliberto, JP | 2 |
| Dibildox, D | 1 |
| Merati, A | 1 |
| Bowen, AJ | 1 |
| Nowacki, AS | 1 |
| Contrera, K | 1 |
| Trask, D | 1 |
| Kaltenbach, J | 1 |
| Milstein, CF | 1 |
| Benninger, MS | 1 |
| Taliercio, R | 1 |
| Dong, R | 2 |
| Ding, H | 1 |
| Pan, J | 1 |
| Yu, Y | 1 |
| Chen, Q | 1 |
| Zhang, M | 1 |
| Lv, H | 1 |
| Qiu, Z | 2 |
| Naik, RD | 1 |
| Vaezi, MF | 1 |
| Wu, CH | 1 |
| Gunasekara, K | 1 |
| Hull, JH | 1 |
| Bikov, A | 1 |
| Morris, AJ | 1 |
| Usmani, OS | 1 |
| Ryan, NM | 2 |
| Gibson, PG | 3 |
| Vertigan, AE | 2 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Cohen, SM | 2 |
| Misono, S | 2 |
| Greene, SM | 1 |
| Simpson, CB | 1 |
| Norris, BK | 1 |
| Schweinfurth, JM | 1 |
| Birring, SS | 1 |
| Lee, B | 1 |
| Woo, P | 1 |
| Persaud, R | 1 |
| Frosh, A | 1 |
| Mintz, S | 2 |
| Lee, JK | 2 |
| Mishriki, YY | 1 |
8 reviews available for gabapentin and Cough
| Article | Year |
|---|---|
Pharmacotherapeutic Options for Chronic Refractory Cough.
Topics: Analgesics, Opioid; Antitussive Agents; Chronic Disease; Cough; Gabapentin; Humans; Pyrimidines; Qua | 2020 |
Management of chronic refractory cough in adults.
Topics: Adult; Asthma; Chronic Disease; Cough; Gabapentin; Humans; Quality of Life | 2020 |
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Gabapentin in chronic cough.
Topics: Amines; Animals; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2015 |
Management of chronic refractory cough.
Topics: Adaptation, Psychological; Amines; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
Are neuromodulating medications effective for the treatment of chronic neurogenic cough?
Topics: Amines; Amitriptyline; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2017 |
Evidence for sensory neuropathy and pharmacologic management.
Topics: Adrenergic Uptake Inhibitors; Amines; Amitriptyline; Anticonvulsants; Chronic Disease; Cough; Cycloh | 2010 |
Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review.
Topics: Amines; Amitriptyline; Baclofen; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2013 |
6 trials available for gabapentin and Cough
17 other studies available for gabapentin and Cough
| Article | Year |
|---|---|
[Guidelines for the management of chronic cough in adults].
Topics: Adult; Amitriptyline; Chronic Disease; Cough; Gabapentin; Humans; Quality of Life | 2023 |
Gabapentin alleviated the cough hypersensitivity and neurogenic inflammation in a guinea pig model with repeated intra-esophageal acid perfusion.
Topics: Animals; Cough; Gabapentin; Gastroesophageal Reflux; Guinea Pigs; Hydrochloric Acid; Lung; Neurogeni | 2023 |
A cough that won't go away: Evaluation and treatment in 2 patients.
Topics: Aged; Analgesics, Opioid; Botulinum Toxins; Chronic Disease; Cognitive Behavioral Therapy; Cough; Di | 2020 |
Recurrent Henoch-Schönlein Purpura with bullous rash and pulmonary nodules.
Topics: Biopsy, Fine-Needle; Bronchoalveolar Lavage Fluid; Chest Pain; Child; Complement C3; Cough; Female; | 2020 |
Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough.
Topics: Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Female; Gabap | 2017 |
Short- and Long-term Effects of Neuromodulators for Unexplained Chronic Cough.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Cohort Studies; Cough; Dose-Response Relationship, Drug | 2018 |
Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue? Authors' reply.
Topics: Baclofen; Cough; Gabapentin; Gastroesophageal Reflux; Humans; Neurotransmitter Agents | 2019 |
Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue?
Topics: Baclofen; Cough; Gabapentin; Gastroesophageal Reflux; Humans; Neurotransmitter Agents | 2019 |
Gabapentin as a potential treatment for cough syncope.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
Management of recurrent laryngeal sensory neuropathic symptoms.
Topics: Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Cough; Cranial Nerve Diseases; Cyclohexan | 2010 |
Gabapentin: a suppressant for refractory chronic cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Mal | 2012 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Amines; Analgesics; Cough; Cyclohexanecarboxylic Acids; Deglutition Disorde | 2005 |
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologists.
Topics: Amines; Anticonvulsants; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids | 2006 |
Gabapentin in the treatment of intractable idiopathic chronic cough: case reports.
Topics: Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; | 2006 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Amines; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Diagnosis, Diff | 2006 |
Laryngeal neuropathy as a cause of chronic intractable cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Ami | 2007 |